Milano A,Laffaioli RV,Caponigro F.The Proteasome:a worthwhile target for the treatment of solid tumours[J].Eur J Cancer,2007,43(7):1 125-1 133.
[4]
Ozaki S,Tanaka O,Fujii S,et al.Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma[J].Int J Hematol,2007,86(2):180-185.
[5]
Yip KW,Reed JC.Bcl-2Family Proteins and Cancer[J].Oncogene,2008,27(50):6 398-6 406.
[6]
Yu C,Bruzek LM,Meng XW,et al.The role of mcl-1downregulation in the proapoptotic activity of the multikinase inhibitor bay 43-9006[J].Oncogene,2005,24(46):6 861-6 869.
Voorhees PM,Dees EC,O’neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9(17):6 316-6 325.
[9]
Tolis C,Peters GJ,Ferreira CG,et al.Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines[J].Eur J Cancer,1999,35(5):796-807.
[10]
Bauer S,Parry JA,Mühlenberg T,et al.Pro-apoptotic activity of bortezomib in gastrointestinal stromal tumor(gist)cells[J].Cancer Res,2010,70(1):150-159.
[11]
Chong H,Vikis HG,Guan KL.Mechanisms of regulating the raf kinase family[J].Cellular Signalling,2003,15(5):463-439.
[12]
O’connor OA,Portlock C,Moskowitz C,et al.Time to treatment response in patients with follicular lymphoma treated with boaezomib is longer compared with other histologic subtypes[J].Clin Cancer Res,2010,16(2):719-726.
[13]
Lessene G,Czabotar PE,Colman PM.Bcl-2family antagonists for cancer therapy[J].Nat Rev Drug Discov,2008,7(12):989-1 000.
[14]
Heath-Engel HM,Chang NC,Shore GC.The endoplasmic reticulum in apoptosis and autophagy:role of the bcl-2protein family[J].Oncogene,2008,27(50):6 419-6 433.
